Hepatic Steatosis
69
11
11
38
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.8%
4 terminated out of 69 trials
90.5%
+4.0% vs benchmark
4%
3 trials in Phase 3/4
24%
9 of 38 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 38 completed trials
Clinical Trials (69)
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
Siemens Biomarker Multi-modality
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Incidence of Liver Disease-Related Outcomes in People With HIV
MHT and Liver Function in Postmenopausal Women
A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity
Hepatic Mitochondrial Function in Youth
First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases
Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
Cholic Acid for Hepatic Steatosis in Lipodystrophy
Implementation of the Fatty Liver Index in Primary Care
Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink
A Clinical Trial of Chazhu Xiaozhi Decoction Against Non-alcoholic Fatty Liver Disease
Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study